Joseph Pilewski
Pulmonary Disease · Pittsburgh, PANPI 1053386599
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Paragonix Technologies, Inc.. That places this record below the midpoint for pulmonary disease clinicians in PA, where the typical reported total is $988.
Across 1 payment — averaging $122.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paragonix Technologies, Inc.$122
Across 84 payments — averaging $12,313 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$961K
- Incyte Corporation$52K
- Genentech, Inc.$18K
- Insmed, Inc.$3K
What the payments were for
- Food & beverage$122100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paragonix Technologies, Inc. | 1 | $122 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SherpaPak$122
- LIVERguard$122
- LUNGguard$122
- BaroGuard$122
- PancreasPak$122
How this compares
$122 in reported general payments places this provider in the 20th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 498 | $13,399,010 |
| CreonLipase/Protease/Amylase | 195 | $1,390,100 |
| KalydecoIvacaftor | 35 | $898,221 |
| ZenpepLipase/Protease/Amylase | 59 | $528,805 |
| CaystonAztreonam Lysine | 27 | $320,594 |
| PancreazeLipase/Protease/Amylase | 24 | $118,605 |
| PulmozymeDornase Alfa | 18 | $89,709 |
| ColistimethateColistin (Colistimethate Na) | 40 | $42,678 |
| Posaconazole | 22 | $38,071 |
| Everolimus | 19 | $36,940 |
| EliquisApixaban | 30 | $31,666 |
| Breo ElliptaFluticasone/Vilanterol | 51 | $25,311 |
| Envarsus XrTacrolimus | 21 | $22,480 |
| Tacrolimus | 81 | $20,382 |
| LokelmaSodium Zirconium Cyclosilicate | 21 | $15,419 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Pittsburgh
- Tariq CheemaPittsburgh$549K
- Stephen BashedaPittsburgh$455K
- Khalid MalikPittsburgh$144K
- Patrick StrolloPittsburgh$124K
- Frank SciurbaPittsburgh$119K
- Sohini GhoshPittsburgh$112K
- Brian CarlinPittsburgh$102K
- Lewis KlinePittsburgh$99K
- Sally WenzelPittsburgh$70K
- Michael ApostolisPittsburgh$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.